PROCEPT BioRobotics (PRCT) EBIT (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported EBIT for 7 consecutive years, with -$27.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 23.44% year-over-year to -$27.4 million in Q2 2026; TTM through Jun 2026 was -$114.2 million, a 24.48% decrease from a year earlier, with the FY2025 full-year figure at -$103.9 million, down 7.5% from the prior year.
• EBIT was -$27.4 million for Q2 2026 at PROCEPT BioRobotics, up from -$32.6 million in the prior quarter.
• Over five years, EBIT peaked at -$15.7 million in Q1 2022 and troughed at -$32.6 million in Q1 2026.
• A 5-year average of -$25.0 million and a median of -$25.6 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT plunged 80.7% in 2023 and jumped 33.32% in 2024, its largest moves.
• Over 5 years, EBIT stood at -$25.0 million in 2022, then fell by 18.04% to -$29.6 million in 2023, then jumped by 33.32% to -$19.7 million in 2024, then sank by 57.49% to -$31.0 million in 2025, then advanced by 11.76% to -$27.4 million in 2026.
• The last three EBIT figures came in at -$27.4 million (Q2 2026), -$32.6 million (Q1 2026), and -$31.0 million (Q4 2025), per Business Quant data.